Table 2 Risk predictors from univariable analysis for at least one asthma attack defined by American Thoracic Society criteria
Number of future attacks | Total | p Value | ||
|---|---|---|---|---|
0 | ≥1 | |||
Mean age (SD), years | 9.0 (2.3) | 8.6 (2.4) | 9.0 (2.3) | <0.001b |
Age group | ||||
5–6 years, n (%) | 605 (18.6) | 139 (26.5) | 744 (19.7) | <0.001b |
7–10 years, n (%) | 1559 (48) | 244 (46.5) | 1803 (47.7) | |
11–12 years, n (%) | 1087 (33.4) | 142 (27) | 1229 (32.5) | |
Gender | ||||
Female, n (%) | 1407 (43.3) | 235 (44.8) | 1642 (43.5) | 0.525b |
Male, n (%) | 1844 (56.7) | 290 (55.2) | 2134 (56.5) | |
IOTF grade | ||||
Thin, n (%) | 279 (16.5) | 53 (15.5) | 332 (16.3) | 0.941b |
Normal, n (%) | 929 (54.8) | 191 (55.7) | 1120 (55) | |
Overweight, n (%) | 303 (17.9) | 60 (17.5) | 363 (17.8) | |
Obese, n (%) | 183 (10.8) | 39 (11.4) | 222 (10.9) | |
Hayfever diagnosis ever | ||||
Yes, n (%) | 995 (30.6) | 189 (36.0) | 1184 (31.4) | 0.013b |
No, n (%) | 2256 (69.4) | 336 (64.0) | 2592 (68.6) | |
Eczema diagnosis ever | ||||
Yes, n (%) | 1831 (56.3) | 339 (64.4) | 2170 (57.5) | <0.001b |
No, n (%) | 1420 (43.7) | 186 (35.4) | 1606 (42.5) | |
Eosinophil count (x10 9 /L) | ||||
≤0.4, n (%) | 1739 (53.5) | 225 (42.9) | 1964 (52) | <0.001b |
>0.4, n (%) | 1512 (46.5) | 300 (57.1) | 1812 (48) | |
Overall asthma control | ||||
Controlled, n (%) | 2534 (77.9) | 234 (44.6) | 2768 (73.3) | <0.001b |
Uncontrolled, n (%) | 717 (22.1) | 291 (55.4) | 1008 (26.7) | |
Asthma attack in baseline year | ||||
0, n (%) | 2853 (87.8) | 285 (54.3) | 3138 (83.1) | <0.001b |
1, n (%) | 317 (9.8) | 143 (27.2) | 460 (12.2) | |
≥2, n (%) | 81 (2.5) | 97 (18.5) | 178 (4.7) | |
LRTI consultations resulting in script for antibiotics | ||||
0, n (%) | 2910 (89.5) | 421 (80.2) | 3331 (88.2) | <0.001b |
1, n (%) | 280 (8.6) | 82 (15.6) | 362 (9.6) | |
2+, n (%) | 61 (1.9) | 22 (4.2) | 83 (2.2) | |
GINA management step | ||||
0, n (%) | 616 (18.9) | 52 (9.9) | 668 (17.7) | <0.001b |
1, n (%) | 395 (12.2) | 47 (9.0) | 442 (11.7) | |
2, n (%) | 1726 (53.1) | 258 (49.1) | 1984 (52.5) | |
3, n (%) | 381 (11.7) | 96 (18.3) | 477 (12.6) | |
4, n (%) | 125 (3.8) | 67 (12.8) | 192 (5.1) | |
5, n (%) | 8 (0.2) | 5 (1.0) | 13 (0.3) | |
Daily SABA dosage (μg) | ||||
None, n (%) | 715 (22.0) | 62 (11.8) | 777 (20.6) | <0.001b |
1–100, n (%) | 410 (12.6) | 55 (10.5) | 465 (12.3) | |
101–200, n (%) | 925 (28.5) | 139 (26.5) | 1064 (28.2) | |
201–300, n (%) | 558 (17.2) | 89 (17.0) | 647 (17.1) | |
301+, n (%) | 643 (19.8) | 180 (34.3) | 823 (21.8) | |
Average ICS daily dose (BUD equivalent) (μg) | ||||
None, n (%) | 1032 (31.7) | 102 (19.4) | 1134 (30.0) | <0.001b |
<100, n (%) | 796 (24.5) | 120 (22.9) | 916 (24.3) | |
101–200, n (%) | 708 (21.8) | 104 (19.8) | 812 (21.5) | |
>200, n (%) | 715 (22) | 199 (37.9) | 914 (24.2) | |
Percent predicted peak flow readings (%) | ||||
N (% non-missing) | 1878 (57.8) | 338 (64.4) | 2216 (58.7) | 0.020a |
Mean (SD) | 102.89 (25.53) | 99.06 (28.24) | 102.30 (25.99) | |
Median (IQR) | 101.1 (86.2, 117.7) | 98.3 (79.5, 117.3) | 100.6 (84.8, 117.6) | |
Median year at start of outcome years (IQR) | 2007 (2005, 2008) | 2007 (2005, 2008) | 2007 (2005, 2008) | 0.257b |
